Gilead is committed to ensuring that individuals at risk of HIV have access to Truvada for PrEP® (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg) tablets. We support comprehensive payer coverage and maintain the Gilead Advancing Access® program for qualified individuals in the United States who cannot afford their medications. This includes our Truvada for PrEP Medication Assistance Program (MAP), which assists eligible HIV-negative adults in the United States who require assistance paying for Truvada for PrEP (pre-exposure prophylaxis).

To ensure we are addressing the affordability challenges, Gilead regularly evaluates its support programs for individuals at risk of HIV who are either considering or taking Truvada for PrEP.

We are pleased to announce an enhancement to the Gilead MAP program:

  • Effective July 1, 2018, individuals who qualify for the MAP will be eligible for 12 months rather than six months. This change will make it easier for individuals to enroll and remain in the program.

To find out if you are eligible for this medication assistance program, call 1-855-330-5479, Monday through Friday between 9:00 a.m. and 8:00 p.m. (Eastern), or visit www.gileadadvancingaccess.com to learn more about the program, including the financial support that may be available for Truvada for PrEP.